News
-
-
-
-
PRESS RELEASE
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer reports solid financial results in 2024 with revenue up 2.9% and adjusted EBITDA up 4.1%. Strategies for growth include expansions and focus on biologics solutions. Bormioli Pharma integration to boost revenues from 2025 -
-
-
-
-
-
PRESS RELEASE
BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division
BRAIN Biotech AG reports 11% organic growth in Q1 of FY 24/25 for BRAINBiocatalysts, forecasts strong growth and solid EBITDA margin, maintains strong cash position of €17.8 million